Luminex CYP2C19 Assay Cleared by FDA, CE Marked in Europe | GenomeWeb

NEW YORK (GenomeWeb News) – Luminex said after the close of the market on Monday that its xTAG CYP2C19 kit has been cleared for marketing by the US Food and Drug Administration and has received the CE Mark in Europe.

The test is intended to aid physicians in determining treatment plans based on genetic variants in the P450 2C19 gene. CYP2C19 is a gene that encodes a phase one drug metabolizing enzyme. The CYP2C19 enzyme is responsible for metabolizing a number of prodrugs and drugs for treating ailments such as ulcers, seizures, malaria, and anxiety, Luminex said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.